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Abstract
Background: UK guidelines recommend routine HIV testing in healthcare settings if the local diagnosed HIV prevalence .2/
1000 persons. This prospective study assessed the feasibility and acceptability, to patients and staff, of routinely offering HIV
tests in four settings: Emergency Department, Acute Care Unit, Dermatology Outpatients and Primary Care. Modelling
suggested the estimated prevalence of undiagnosed HIV infection in attendees would exceed 1/1000 persons. The
prevalence identified prospectively was not a primary outcome.
Methods: Permanent staff completed questionnaires assessing attitudes towards routine HIV testing in their workplace
before testing began. Subsequently, over a three-month period, patients aged 16–65 were offered an HIV test by study staff.
Demographics, uptake, results, and departmental activity were collected. Subsets of patients completed questionnaires.
Analyses were conducted to identify factors associated with test uptake.
Findings: Questionnaires were received from 144 staff. 96% supported the expansion of HIV testing, but only 54% stated
that they would feel comfortable delivering testing themselves, with 72% identifying a need for training. Of 6194 patients
offered a test, 4105 (66?8%) accepted (61?8–75?4% across sites). Eight individuals were diagnosed with HIV (0–10/1000
across sites) and all transferred to care. Younger people, and males, were more likely to accept an HIV test. No significant
associations were found between uptake and ethnicity, or clinical site. Questionnaires were returned from 1003 patients.
The offer of an HIV test was acceptable to 92%. Of respondents, individuals who had never tested for HIV before were more
likely to accept a test, but no association was found between test uptake and sexual orientation.
Conclusions: HIV testing in these settings is acceptable, and operationally feasible. The strategy successfully identified, and
transferred to care, HIV-positive individuals. However, if HIV testing is to be included as a routine part of patients’ care,
additional staff training and infrastructural resources will be required.
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Introduction
In 2009, an estimated 26% of all adults living with HIV
infection in the UK were thought to be undiagnosed. [1] Of those
newly diagnosed, more than half presented at a late stage, with a
CD4 count of less than 350 per ml. [1] Late diagnosis of HIV
infection is associated with poorer responses to antiretroviral
therapy [2,3] and a worse prognosis. [4] A substantial number of
HIV-infected individuals will present to health care providers with
symptoms attributable to HIV infection in the period preceding
their diagnosis, without the underlying diagnosis being made. [5]
Beyond the value to the individual, efforts to reduce the
undiagnosed fraction may have public health benefits. An
estimated 50% of new HIV infections in the US are transmitted
by the 25% of HIV-positive individuals unaware of their status. [6]
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antiretroviral therapy reduces transmission risk: thus earlier
diagnosis is likely to reduce HIV transmission at a population
level. [8].
Guidance from the National Institute for Health and Clinical
Excellence (NICE) joins existing recommendations from the Chief
Medical and Nursing Officers, the British Association for Sexual
Health and HIV, the British HIV Association and the British
Infection Society in calling for the expansion of HIV testing to
settings beyond sexual health clinics and antenatal care. [9–12]
One recommendation is that HIV testing should be offered to all
general medical admissions and primary care registrants in areas
where the diagnosed prevalence of HIV infection exceeds 2 per
1000 persons. Thirty-seven Primary Care Trusts exceed this
prevalence threshold. [1].
Routine HIV testing in antenatal care and sexual health clinics
in the UK has greatly increased HIV testing rates. [1,13] Routine
testing has been shown in an RCT to be acceptable to patients and
to cause no undue anxiety. [14] In the US, the CDC has
recommended routine testing for all individuals aged 13 to 64
presenting to any healthcare facility since 2006. [15] In those
States that have implemented this guidance, the number of new
HIV diagnoses has risen, and the proportion of individuals
diagnosed late has fallen. [16] No data exists in the UK regarding
how such programmes may function within the health service. The
HIV Testing in Non-traditional Settings (HINTS) study was
conceived to investigate the feasibility and acceptability, to patients
and staff, of delivering routine HIV testing in non-specialist
settings, in areas of high HIV prevalence.
Methods
(1) Clinical Sites, Study Participants and Methods
The HINTS study was an observational study conducted at four
locations in London, UK: an Emergency Department (ED), an
Acute Care (medical and surgical admissions) Unit (ACU), a
Dermatology Outpatient Clinic (OPD), and a Primary Care
Centre (PC). All are located within areas of diagnosed HIV
prevalence .2/1000 persons as per the Health Protection
Agency’s Survey of Prevalent HIV Infections Diagnosed (SOPHID)
dataset (Table 1). Pre-study modelling using this dataset, combined
with estimated HIV-undiagnosed fractions from national unlinked
anonymous seroprevalence surveys, demonstrated that the esti-
mated prevalence of undiagnosed HIV infection amongst attend-
ees in all four settings would exceed 1/1000 persons - the
suggested cost effectiveness threshold in UK guidelines (data not
shown).
The study was divided into two phases. During the pre-study
phase, a questionnaire was administered to all clinical and support
staff within each department, assessing attitudes and knowledge
towards HIV infection and the provision of HIV testing in non-
specialist settings. All staff were encouraged to respond, and the
return rate was calculated. The majority of staff completing the
questionnaire were not directly involved in delivering the
subsequent HIV testing programmes (see below).
During the study phase, HIV testing was offered to all
sequential patients accessing the healthcare setting, who fulfilled
the inclusion criteria, as follows: aged between 16 and 65 years and
(i) not known to be HIV positive, (ii) accessing the healthcare
setting for the first time over the testing period, and (iii) able to
consent to a test. A leaflet was provided and verbal consent was
obtained prior to HIV testing. Delivery of HIV testing in these
settings was in line with published National guidelines, [10] and as
such, verbal consent only to an HIV test was deemed sufficient,
and in line with good clinical practice in the UK. The leaflet was
available in multiple languages. In the ED, ACU and OPD, tests
were offered by super-numerary study staff. These staff comprised
seconded local sexual health and permanent departmental staff,
and a small number of non-clinical staff. In the PC arm, testing
was delivered by general practitioners during clinical consulta-
tions. All staff offering tests had received focussed didactic and
practical training in the provision of HIV tests before the study
began (see Table 1). Results governance and delivery was
managed by the local Sexual Health service. Patients with a
reactive HIV test were recalled to undergo confirmatory HIV
testing. A helpline number was provided, and sexual health
counsellors were available to all patients upon request.
Oral fluid-based HIV testing was used in the PC, ED and OPD
arms, and was performed using a fourth-generation assay on a
modified platform to detect HIV-1 antibodies. Internal validation
of this technique in the pre-study phase showed it to be robust.
[17] In the ACU, fourth generation HIV serology was performed
on serum samples obtained during the inpatient admission
(Table 1).
Questionnaires were administered to sequential patients offered
HIV tests at prospectively planned intervals throughout the testing
period, in order to minimise selection bias. The questionnaire
distribution strategy was designed in a pragmatic fashion, in order
to maximise the amount of time during which HIV testing was the
only additional intervention. As provision of the questionnaire
required additional time, it impacted upon the number of tests that
could be offered; therefore questionnaires were offered only on
pre-determined days. On these days, questionnaires were sequen-
tially offered to all patients who were eligible for the study (both
those who accepted testing and those who declined). The
questionnaire collected basic demographic data, HIV testing
behaviour, and attitudes towards a series of statements on HIV
testing, quantified by modified Likert scales. In the PC arm, active
recruitment to the questionnaire study was also supplemented
retrospectively by a mobile phone text recruitment campaign.
(2) Ethics
Full, verbal consent was sought prior to HIV testing, in line with
good clinical practice (as per General Medical Council guidance)
and in line with the published, national, clinical guidelines. [10]
Written consent to test was thus deemed unnecessary and viewed
as a potential disincentive to test. The outcome of the test offer was
recorded in the case notes. Questionnaires were fully anonymous
and verbal consent was sought prior to completion. A favourable
ethical opinion to conduct the research in the manner described
above was obtained from the UK National Research Ethics
Service (REC reference: 09/H0805/35) which confers freedom to
conduct the research across all National Health Service settings in
the UK, subject to local Research and Development Office
registration. Such registration to conduct the research was
obtained in all four National Health Service settings: Chelsea
and Westminster NHS Foundation Trust, London; Homerton
University Hospital Foundation Trust, London; Kings College
Hospital NHS Foundation Trust, London; North End Medical
Centre, NHS Hammersmith and Fulham, London (Table 1).
(3) Primary Outcomes
The primary outcome measures of the study comprised:
N feasibility of delivering routine HIV testing in the non-
specialist setting, as evaluated by measuring the proportion
of eligible individuals offered tests
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site, as evaluated by test uptake and the results of the patient
and staff questionnaires
N proportion of individuals newly diagnosed with HIV infection
in non-specialist settings successfully transferred to specialist
HIV clinical care
(4) Sample Size and Data Capture
A modelling exercise (described in the Methods section) was
undertaken to estimate the prevalence of undiagnosed HIV in the
populations using each setting. At a projected 2/1000 persons,
measuring the true prevalence of undiagnosed HIV in the study
settings to within +/20?05% would require sampling of .30 000
Table 1. HINTS Study Sites.
Study Site
Primary Care
Trust (PCT)
Diagnosed HIV
prevalence per
1000 individuals
15–59 years
living in PCT
(ranking in UK)
[1]
Model of routine HIV testing
service delivery: Composition of
HIV testing team (TT)
Delivery model (DM)
Testing phase: weeks
(dates conducted)
HIV testing method: Sample
(S) Assay (A) Platform (P)
Confirmation (C)
Chelsea and Westminster
Hospital Emergency
Department (ED) (45 000
attendances/annum)
Kensington and
Chelsea
8?33 (4
th) TT: seconded staff from ED,
Sexual Health, non-clinical testers
15 (August-November
2009)
S: Oral fluid (whole saliva
sample)
DM: two testers per testing shift
on a rolling rota; planned coverage
of all time periods and days
A: Bio-Rad Genscreen Ultra HIV
Ag-Ab EIA test (Bio-Rad
laboratories, Hertfordshire, UK)
P: Biokit Best 2000 (Launch
Diagnostics, Kent, UK)
C: Abbott Determine HIV 1/2
test (Abbott Diagnostics,
Berkshire, UK)
Homerton University
Hospital - Acute Care Unit
(ACU) (4200 attendances/
annum)
City and Hackney 8?25 (5
th) TT: seconded staff from mixed
backgrounds (ED, Sexual Health,
non-clinical testers, research nurse)
12 (January-April 2010) S: Whole serum
DM: single tester reviewed electronic
bed state once daily and approached
all age-eligible patients admitted
in the preceding 24 hours,
still present in the ACU
A: Abbott Architect HIV Ag/Ab
4
th generation assay (Abbott
Diagnostics, Berkshire, UK)
P: Abbott Architect ci8200
Integrated System (Abbott
Diagnostics, Berkshire, UK)
C: Confirmation on repeat
Kings College Hospital -
Dermatology Outpatient
Department (OPD) (5000
attendances/annum)
Lambeth 13?28 (1
st) TT: seconded staff from mixed
backgrounds (dermatologists, Sexual
Health, non-clinical testers, medical
students)
12 (July–September
2010)
S: Oral fluid (sample collection
with Oracol+ device, Malvern
Medical Developments PLC,
Worcestershire, UK)
DM: two testers present in each
Clinic. Patients offered HIV test
prior to Dermatology consultation
A: Bio-Rad Genscreen Ultra HIV
Ag-Ab EIA test (Bio-Rad
laboratories, Hertfordshire, UK)
P: TECAN RMP200 (Tecan UK
Ltd, Berkshire, UK)
C: Confirmation on repeat
North End Medical Centre -
Primary Care (PC) 13 671
registered patients aged
16–65 (2010)
Hammersmith and
Fulham
8?15 (6
th) TT: all GPs and nurse practitioners
in the practice who had received
focussed training
14 (February-May 2010) S: Oral fluid (sample collection
with Oracol+ device, Malvern
Medical Developments PLC,
Worcestershire, UK)
DM: testing introduced to routine
consultations in a staggered fashion
A: Bio-Rad Genscreen Ultra HIV
Ag-Ab EIA test (Bio-Rad
laboratories, Hertfordshire, UK)
P: Biokit Best 2000 (Launch
Diagnostics, Kent, UK)
C: Abbott Determine HIV 1/2
test (Abbott Diagnostics,
Berkshire, UK)
[1] Health Protection Agency. HIV in the United Kingdom 2010. Health Protection Agency; 2010 [accessed 24th January 2011]; Available from: http://www.hpa.org.uk/
Publications/InfectiousDiseases/HIVAndSTIs/1011HIVUK2010Report/.
doi:10.1371/journal.pone.0039530.t001
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outcome of the study. In order to answer our primary outcomes of
feasibility of delivering testing, and of staff and patient accept-
ability, it was decided to time-limit the trial, with a minimum of
twelve weeks testing at each site. We projected reaching 8000
patients for testing, and administering 1000 patient questionnaires.
Electronic patient records were used to capture age, sex,
ethnicity, reasons for non-offer of HIV test (including ineligibility)
and the outcome of the test offer. All data were anonymised prior
to analysis. Data were held in line with the Data Protection Act
1998 and local Trust policies.
(5) Statistical Analysis
Operational (feasibility) data (populations attending, test offer
rate, test uptake) were analysed by site, and differences were
assessed for associations using the x
2–test, with Yates’ correction
applied where appropriate.
Univariate logistic regression analysis was used to examine
factors that were associated with the likelihood of test uptake, and
this was stratified by clinical site, as differences in accepting an
HIV test were found by site. The strata specific adjusted estimates
found to be significant (p,0?2) in the univariate model were used
to derive a multivariable logistic regression model. In order to
ensure no degrees of freedom were lost when building a
multivariable model, all variables with missing data were coded
with a separate category. The final multivariable model presented
has been stratified by clinical site. Stratified logistic regression
analyses were repeated, based on data from the subset of patients
who completed the questionnaire (the questionnaire collected
additional variables: previous HIV testing behaviour and self-
reported sexuality).
(6) Clinical Trial Registration
This study was registered on ClinicalTrails.gov with the Study
ID: NCT01138878, in line with local requirements.
Results
(1) Staff Attitudes Towards HIV Testing
Pre-study staff questionnaires were completed by 146 members
of staff in each of the departments (57 doctors, 56 nurses, 14
allied health professionals and 19 clerical staff). The return rate
was: ED 91%; ACU 76%; OPD 82%; PC 92%. Staff members
in all departments were supportive of the provision of HIV tests
in non-specialist settings and of the provision of HIV testing
within their department (Table 2). However, a smaller propor-
tion of doctors and nurses felt comfortable offering the HIV test
to patients themselves (ED 57%; ACU 42%; PC 75%; OPD
63%). Analysis of topic areas suggested that the majority of staff
at all four sites felt they would require additional training before
routinely offering HIV tests to patients (overall: 72% (95%CI 64–
80%)). A smaller proportion identified operational barriers, such
as a lack of time.
(2) HIV Testing
(2.1) Populations offered testing. Across all four sites, there
were 13 855 age eligible attendees, of whom 7033 (50?7%) were
approached by study personnel (Table 3). Of this number, 839
(11?6%) were subsequently considered ineligible to test. The
reasons for clinical ineligibility to test across the sites are shown in
Figure 1, as proportions of the total at each site. Significant
differences were seen in both the approach rate and proportion
clinically ineligible to test across the sites (p,0.05 for both
comparisons). Differences were also observed between the
populations of patients approached for testing, versus the entire
populations of eligible patients attending. With respect to the total
eligible population, patients approached were more likely to be
male (43?9% vs. 37?0%), and less likely to be of Black African
origin (5?0% vs. 7?2%) (p,0?05 for both comparisons). Analysis of
data by site indicates this was mainly driven by differences
observed in the PC and ED arms (data not shown).
(2.2) HIV testing data. Of the 6194 patients offered an HIV
test, 4105 accepted this offer: test uptake =66?8% (Table 3). Eight
individuals were newly diagnosed with HIV infection, and all were
successfully transferred to care (two partners were subsequently
diagnosed with HIV infection through partner notification). HIV
seropositivity across the sites was 1.9/1000 persons (95% CI 0?6–
3?2/1000). Significant differences in seropositivity are noted
between sites (p,0.05). There were seven false reactive screening
tests (2 in ED and 5 in PC) as confirmed by further serological
testing. These all related to oral fluid HIV screening tests. There
were no false reactive screening tests in the ACU arm, where
serology was performed.
Uptake of HIV testing differed significantly by site; range:
61?8%–75?4% (ED vs. PC) (p,0?001). The multivariable model
demonstrated that sex, age and the profession of the test provider
were significantly associated with test uptake. Male patients and
younger patients were more likely to accept tests. Patients were
more likely to accept tests when offered the test by a medical
student or doctor, rather than by a nurse or a trained tested from a
non-clinical background (Figure 2). Site per se was not an
independent predictor of test uptake.
(3) Patient Questionnaire Data
(3.1) Patient questionnaire respondents. A total of 1003
questionnaires were returned during the testing phase. The
number of questionnaires received from each site (n) was not
proportional (%) to the total numbers of patients offered testing:
ED=528 (15?3%), ACU=107 (19?5%), OPD=297 (33?6%),
PC=71 (5?3%). We are unable to calculate a return rate on
questionnaires due to operational differences in the questionnaire
study across the sites. In relation to the total population (n=6194)
questionnaire respondents were younger (mean age yrs (SD): 36?0
(12?2) vs. 37?6 (12?8)), more likely to be White (69?9% vs. 56?8%),
and more likely to have accepted an HIV test (73?5% vs. 66?8%
overall) (p,0?001 for all comparisons).
(3.2) Predictors of HIV test acceptance. Using data
derived from questionnaire respondents only, previous HIV
testing behaviour was shown to be associated with test uptake:
48?5% of respondents had never tested for HIV infection, and this
group was more likely to accept an HIV test than those who had
previously tested (unadjusted RR 1?00 versus 0?65 (95% CI 0?49–
0?87) p=0?007). A trend was observed amongst previous testers
with those having tested recently (less than one year ago) being the
least likely to accept an HIV test, and those having tested between
two and five years previously the most likely (p,0?001; x
2 for
trend). The multivariable analysis is shown in Figure 3.
(3.3) Reasons for declining an HIV test. Questionnaire
respondents who had declined an HIV test (n=265) were asked to
cite reasons for doing so. Respondents could cite more than one
reason. The most commonly cited reasons, across all four sites,
were: ‘‘I have tested recently’’ (54%), ‘‘I do not think I am risk of
HIV infection’’ (47%), and ‘‘I have other health concerns today’’
(24%).
(3.4) Patient acceptability of HIV testing. In response to
the statement: ‘‘It is acceptable to me to be offered an HIV test in this
setting,’’ 92% of 1003 questionnaire respondents agreed. Of those
accepting an HIV test, this proportion was 97%; in those
HIV Testing in Non-Traditional Settings - HINTS
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acceptability was associated with younger age and male sex, plus
test uptake. No difference was seen by ethnicity or by clinical
site. In multivariable analysis, stratified by clinical site, the
acceptability of testing remained positively associated with male
sex (RR 2?05 (95%CI 1?12–3?76) p=0?02) and with younger age
groups (,27 yrs RR 2?35 (95%CI 1?03–5?37) p=0?043). HIV
test acceptance was a strong predictor of acceptability (RR in test
decliners: 0?22 (95%CI 0?13–0?38) p,0?001). Levels of support
to a series of statements advocating the expansion of HIV testing
to non-specialist settings were high in both test accepters and test
decliners, and were in excess of 90% in all cases.
Discussion
What is Already known on this Topic?
The delivery of routine HIV testing in non-specialist medical
settings in areas of high HIV prevalence (more than 2 diagnosed
cases/1000 persons) is advocated by National Guidelines in the
UK. Whilst data exists in the US, there is, to date, no published
Table 2. Staff attitudes and barriers to the provision of HIV tests in non-specialist settings.
Proportion agreeing with statement (maximum
number of respondents to question) [95% CI]
ACU
(41) ED (71) PC (14) OPD (18) OVERALL (144)
Attitudes
‘‘HIV testing should be available in services other than sexual health and antenatal clinics’’ 98% 94% 100% 100% 96% [93–99]
‘‘HIV testing should be routinely offered to everyone’’ 81% 84% 87% 83% 83% [77–89]
‘‘Offering HIV testing to all patients in this department is a good idea’’ 79% 80% 79% 83% 80% [73–86]
‘‘I would feel comfortable offering HIV testing to all patients in this department’’ 42% 57% 75% 63% 54% [45–63]
Barriers
‘‘I don’t think this department provides enough privacy to routinely offer an HIV test to all patients’’ 44% 58% 0% 17% 43% [35–51]
‘‘I am concerned that patients would have questions I could not answer’’ 52% 72% 57% 53% 63% [55–70]
‘‘I don’t have time to include routine HIV testing as part of patients’ care in this department’’ 40% 53% 38% 27% 44% [45–53]
‘‘I would require additional training before routinely offering HIV tests to patients’’ 65% 82% 56% 63% 72% [64–80]
doi:10.1371/journal.pone.0039530.t002
Table 3. Coverage, uptake and seropositivity of routine offer of HIV test across the four sites.
ED ACU PC OPD
Age eligible attendees
(n=15 042)
5541 1388 6337 1776
Total study eligible
attendees (first offer of
test; not known
HIV-positive) (%)
(n=13 855) [95% CI]
5505 (99?3%) [99?1%–99?6%] 1298 (93?5%) [92?2%–94?8%] 5352 (84?5%) [83?6%–85?4%] 1700 (95?9%) [94?8%–
96?7%]
Coverage = eligible
attendees approached (%)
(n=7033) [95% CI]
4070 (73?9%) [72?7%–75?1%] 623 (48?0%) [45?3%–50?8%] 1442 (26?9%) [25?8%–28?1%] 898 (52?8%) [50?5%–55?2%]
Clinically ineligible
(% of all approached)
(n=839) [95% CI]
637 (15?7%) [14?5%–16?8%] 75 (12?0%) [9?5%–14?6%] 113 (7?8%) [6?5%–9?2%] 14 (1?5%) [0?8%–2?4%]
Total tests offered (n=6194) 3433 548 1329 884
Uptake = total tests
accepted (%)
(n=4105) [95% CI]
2121 (61?8%) [60?2%–63?4%] 384 (70?1%) [66?2%–74?0%] 1002 (75?4%) [73?1%–77?7%] 598 (67?6%) [64?6%–70?7%]
Reactive HIV tests (n=15) 64 50
False reactive HIV tests (n=7) 20 50
Newly diagnosed
individuals (n=8)
44 00
HIV seropositivity
(per 1000) [95% CI]
1?9[ 0 ?05–3?8] 10?1[ 0 ?3–20?5]
Proportion transferred
to care
100% 100% n/a n/a
doi:10.1371/journal.pone.0039530.t003
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routine HIV testing in general medical settings within the context
of the UK health service. The HINTS Study was conceived to
generate an evidence base to inform the development of testing
services in the UK.
What does Our Study Add?
Our study shows that it is acceptable to the majority of patients
to be offered an HIV test in a non-specialist setting. Uptake of
testing is high across all socio-demographic categories, assuaging
concerns that higher risk individuals may be less likely to accept a
test in such settings. Patients declining to test still found it
acceptable to be offered the test. Many patients accepting a test
had never tested for HIV infection before. Cases of undiagnosed
HIV were identified, and all patients were successfully transferred
to clinical care. Staff members from the departments involved in
the study were supportive of the initiative, but many identified
educational needs and operational barriers that would need to be
addressed if they were to deliver routine HIV testing in the long
term.
The HINTS study is the first published data regarding routine,
non-targeted testing within secondary care in the UK, and
provides evidence on how such a strategy may operate within the
UK health service. More than 6000 patients were offered an HIV
test, and more than 4100 consented. The uptake of HIV testing
across the sites of 66?8% compares favourably with (and in many
cases is substantially superior to) uptake rates observed in US
settings, and from preliminary reports from other pilot studies in
operation in the UK and France. [18–22].
The coverage rates are substantially higher than those reported
in most US settings. In ED-based programmes in the US,
programmes employing near-patient testing augmented by coun-
sellors have managed to reach much smaller fractions (typically
,5%) of all eligible patients passing through. [19,21,23] The
testing intervention in the HINTS Study was brief and augmented
by written information. Testing was delivered in line with national
guidelines, and lengthy pre-test counselling was not felt to be
appropriate within the clinical settings used. Pre-test counselling
has not been shown to reduce subsequent HIV transmission risk in
a large meta-analysis, [24] but test providers during HINTS were
Figure 1. Reasons for clinical ineligibility to participate by site (proportion of total ineligible (%)).
doi:10.1371/journal.pone.0039530.g001
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basis. Coverage was likely also increased by not employing near-
patient tests, which require clinical expertise and time, and may
not sit well within the time-pressured environments of the NHS.
Near-patient tests have been associated in US settings with better
transfer to care rates and greater acceptability to patients. [21,25]
Our transfer to care rate was 100%. This was likely a function of
the co-operation between the testing site and the local Sexual
Health service. In the OPD and ACU sites, the population of
patients offered HIV tests was representative of the entire
population. This suggests no targeting was evident at these sites.
In the PC and ED arms, targeting of male patients appears
evident, and fewer than expected tests were offered to patients of
Black African origin. This is an interesting observation with
respect to the ethnic disparity, as it contradicts the expectation that
if targeting were present, it would be directed towards those who
belong to higher risk populations.
There are several differences between the sites that merit special
mention. The seropositivity of previously undiagnosed HIV is
significantly different across the sites, with 1.9/1000 and 10.1/
1000 HIV-infected persons identified in the ED and ACU settings,
and no new diagnoses made in the OPD and PC settings. It is
essential to interpret these figures with due caution, as seropos-
itivity was not a primary outcome of the study (as it was not
possible to sufficiently power the study to demonstrate this with
statistical confidence) but the significant difference between the
ED and ACU populations is of interest; it may be related to the
acute nature of the settings and the possibly greater severity of
presenting complaints, and certainly warrants further investiga-
tion. Differences in prevalence across healthcare settings may have
clinical and cost benefit implications. The higher case finding rate
in inpatient settings may be tempered by differences in the clinical
status of patients diagnosed here, as evidenced by UK surveillance
data which demonstrate that patients diagnosed as inpatients have
lower median CD4 counts and worse outcomes. [1].
The proportions of patients offered testing and the proportions
deemed ineligible to participate are also different. This may reflect
differences in the patient populations attending each setting, but
may also reflect operational differences such as different staffing
arrangements. Large patient throughput in the ED, for example,
meant two testers needed to be present to offer testing at all times,
whereas in the ACU a lone tester making a daily round was
deemed sufficient (see Table 1 for details). The coverage in the
ACU was limited, however, by the short median stay on the unit:
this meant many patients had been discharged before the HIV test
offer could be made. Greater proportions of patients were deemed
ineligible to test in the acute settings of the ED and ACU, with
respect to the non-acute OPD and PC settings: greater numbers of
patients were too medically unwell to consent to a test, for
example. In the ED, insurmountable language barriers precluded
testing in a number of patients, reflecting the particular
characteristics of this patient population, and despite our offering
of pre-test literature in a number of languages and the availability
of interpretation services.
Figure 2. Multivariable logistic regression model showing significant independent predictors of HIV test uptake in patients who
were offered the test. (n=6194; adjusted for ethnicity, and other variables in the model, and stratified by site).
doi:10.1371/journal.pone.0039530.g002
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related to the use of oral fluid. With a total of 11 reactive oral fluid
tests of 3717 oral fluid tests done, the specificity of the oral fluid
test is 99.8% with a positive predictive value of 36%. The positive
predictive value will remain a function of the prevalence of true
HIV infection in the population tested, and both this figure and
the test specificity are acceptable in this context. All patients with
reactive screening tests were successfully informed of their results,
and all but one returned had their confirmatory testing undertaken
in local sexual health service. All of this group found this process
acceptable.
Concerning HIV test uptake, the two adjusted models (overall
data and questionnaire respondents only) show age, sex, previous
testing behaviour and test provider to be independent predictors of
likelihood of test uptake, when stratified by clinical site. However,
uptake across all socio-demographic categories was good, specif-
ically amongst MSM and minority ethnic groups. This assuages
our concerns that higher risk individuals may be less likely to
accept an HIV test in a non-specialist setting. Never having
previously tested was also positively associated with test uptake.
This suggests offering HIV tests in non-specialist settings brings the
opportunity of an HIV test to a population who might not
otherwise present for one, and that this group welcomes the
opportunity. It is important not to assume that patients who
decline an HIV test do so because they find it unacceptable. Many
patients declining an HIV test did so for understandable reasons.
There remained a significant proportion of test decliners who felt
that they ‘‘were not at risk of HIV infection’’ and this merits
investigation in future work. However, the majority of question-
naire respondents (92%) found the offer of an HIV test in the non-
specialist setting acceptable, including 85% of test decliners. Few
differences in attitude were observed between test accepters and
decliners. The overall level of acceptability is greater than the 72%
reported by Drayton et al’s survey of patient attitudes to routine
testing in the UK. [26].
Whilst staff are accepting of expanding HIV test provision,
barriers to implementation at the staff level are evident. Some of
the barriers identified are operational in nature, and echo those
identified in US ED-based research. [27,28] Concerns include a
lack of time to conduct testing and being ill-prepared to answer
patient queries. Testing in this study was delivered in all but one
setting (PC) by seconded staff. We cannot therefore generalise
many of our operational findings to a service delivery model where
testing is offered as part of routine clinical duties. The close
working with Sexual Health services, particularly in relation to
results governance, recall and transfer to care, was effective, robust
and greatly valued by local staff.
There are limitations to the study. Targeting of test offer at the
PC and ED sites may have introduced selection bias, which the
multivariable analyses and per-site stratification cannot eliminate.
We are unable to report a return rate on the questionnaire study,
and the differences in the respondent population strongly suggest
that questionnaire distribution (and completion) was not system-
atic. The proportion of questionnaire respondents across the sites,
as a fraction of the total number offered testing, was widely
different, for example. The questionnaire was available in English
only, which may explain some of the ethnic disparity, but other
differences are likely to represent offer bias by study staff. As such,
generalisability of the questionnaire data is limited. The unadjust-
ed data and adjusted data must be interpreted within the
populations studied. The fact that clinical site does not appear
to predict test uptake or acceptability of testing in the adjusted
Figure 3. Multivariable logistic regression model showing potential predictors of HIV test uptake in patients who completed the
questionnaire. (n=1003; adjusted for age, ethnicity and other variables in the model, and stratified by site; MSM=men who have sex with men).
doi:10.1371/journal.pone.0039530.g003
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broader population setting. However, as previously discussed,
many of the differences observed between the sites may have been
driven by local operational factors, specific and unique to each
situation. Broader conclusions and interpretations ought to be
limited to the general, cross-site observations that, we believe,
confidently demonstrate that testing is acceptable and efficacious.
Whilst we believe we have shown that routine HIV testing in non-
specialist settings is effective at diagnosing infected individuals, we
have yet to prove such an approach is cost effective. This work is
ongoing. However, the 2/1000 persons diagnosed prevalence
threshold for routine testing advocated in UK guidelines is drawn
from US modelling estimates that suggest a lower threshold of 1/
1000 persons is likely to be highly cost effective. [29].
In conclusion, the HINTS study demonstrates that routine HIV
testing in non-specialist settings in the UK is highly acceptable to
patients and staff. Furthermore, it shows such a strategy is feasible
to deliver in a diverse range of settings, and is effective at
diagnosing HIV-infected individuals and transferring them to care.
As such, the study offers a substantial evidence base to underpin
strong recommendations from specialist societies, clinical effec-
tiveness bodies, and public health agencies in the UK that routine
HIV testing in secondary and primary care settings in areas of high
HIV prevalence, ought to be developed and implemented as a
matter of urgency. The specific logistics of local implementation
will need to be developed within the local context, after
appropriate stakeholder engagement.
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